

***Plasmodium falciparum*, Strain CamWT_C580Y**

Catalog No. MRA-1251

Product Description: *Plasmodium falciparum* (*P. falciparum*), strain CamWT_C580Y is a K13-propeller mutant of the CamWT strain (BEI Resources MRA-1250), featuring a single nucleotide substitution leading to a C580Y amino acid change. *P. falciparum*, strain CamWT_C580Y was deposited as more resistant to artemisinin than the parent strain with a ring-stage survival assay (RSA_{0-3h}) value of 8.9% when exposed to dihydroartemisinin.

Lot¹: 63268018

Manufacturing Date: 23JAN2015

TEST	SPECIFICATIONS	RESULTS
Identification by Giemsa Stain Microscopy²	Blood-stage parasites present	Blood-stage parasites present
Antimalarial Susceptibility Profile (<i>in vitro</i>) Half-maximal Inhibitory Concentration (IC ₅₀) by SYBR green I [®] drug sensitivity assay ³ Chloroquine Artemisinin Quinine Cycloguanil Pyrimethamine Sulfadoxine Ring-stage Survival Assay (RSA _{0-3h}) ⁴ Dihydroartemisin (DHA) ⁵	Report results Report results Report results Report results Report results Report results Report results	53.0 ± 6.1 nM 3.0 ± 0.3 nM 109.5 ± 15.2 nM 960.3 ± 88.6 nM 22690 ± 2618 nM 341100 ± 79237 nM
Genotypic Analysis Sequencing of Merozoite Surface Protein 2 (MSP2) gene (~ 720 base pairs) MSP2 PCR amplicon analysis ⁶	Consistent with <i>P. falciparum</i> ~ 600-900 base pair amplicon	Consistent with <i>P. falciparum</i> (Figure 1) ~ 900 base pair amplicon (Figure 2)
Level of Parasitemia Pre-freeze ⁷ Post-freeze ⁸	Report results > 1%	3.87% 1.19%
Viability (post-freeze)⁹	Growth in infected red blood cells	Growth in infected red blood cells
Sterility (21-day incubation) Harpo's HTYE broth ¹⁰ , 37°C and 26°C, aerobic Tryptic Soy broth, 37°C and 26°C, aerobic Sabouraud Dextrose broth, 37°C and 26°C, aerobic DMEM with 10% FBS, 37°C, aerobic Sheep Blood agar, 37°C, aerobic Sheep Blood agar, 37°C, anaerobic Thioglycollate broth, 37°C, anaerobic	No growth No growth No growth No growth No growth No growth No growth	No growth No growth No growth No growth No growth No growth No growth
Mycoplasma Contamination DNA Detection by PCR	None detected	None detected

¹MRA-1251 was produced by cultivation of the deposited material in fresh human erythrocytes in RPMI 1640 medium, adjusted to contain 10% (v/v) heat-inactivated human serum (pooled Type A), 25 mM HEPES, 2 mM L-glutamine, 4 g/L D-glucose, 0.005 µg/mL hypoxanthine and 2.5 µg/mL gentamicin. The culture was incubated at 37°C in sealed flasks outgassed with blood-gas atmosphere (90% N₂, 5% CO₂, 5% O₂) and monitored for parasitemia daily for 9 days. Every 1 to 2 days, uninfected, leukocyte filtered, Type O erythrocytes in complete culture medium were added dropwise to the culture to maintain 2% hematocrit.

²Blood-stage malaria parasites (rings, trophozoites, schizonts +/- gametocytes) were examined by microscopic Giemsa-stained blood smears of an *in vitro* human blood culture over 5 days.

³A SYBR Green I[®] anti-malarial drug sensitivity assay in 96-well plates was used to determine IC₅₀ values of an active (> 70% ring stage) parasite

culture in the presence of each antimalarial drug [Hartwig, C. L., et al. "XI: I. SYBR Green I®-Based Parasite Growth Inhibition Assay for Measurement of Antimalarial Drug Susceptibility in *Plasmodium falciparum*." In *Methods in Malaria Research Sixth Edition*. (2013) Moll, K., et al. (Ed.), EVIMalaR, pp. 122-129. Available at: <https://www.mr4.org/Publications/MethodsInMalariaResearch.aspx>].

⁴A detailed RSA_{0-3h} protocol is available on the Worldwide Antimalarial Resistance Network's website at <http://www.wwarn.org/tools-resources/procedures/ring-stage-survival-assays-rsa-evaluate-vitro-and-ex-vivo-susceptibility>.

⁵*P. falciparum*, strain CamWT_C580Y was reported with a DHA RSA_{0-3h} value of 8.9% [Straimer, J., et al. "Drug Resistance. K13-Propeller Mutations Confer Artemisinin Resistance in *Plasmodium falciparum* Clinical Isolates." *Science* 347 (2015): 428-431. PubMed: 25502314.].

⁶Primer sequences and conditions for PCR are available upon request.

⁷Pre-freeze parasitemia was determined after 9 days post infection by microscopic counts of Giemsa-stained blood smears.

⁸Post-freeze parasitemia was determined after 5 days post infection by microscopic counts of Giemsa-stained blood smears.


⁹Viability was confirmed by examination of infected erythrocytes for parasitemia (1.19%) at 5 days post infection.

¹⁰Atlas, Ronald M. *Handbook of Microbiological Media*. 3rd ed. Ed. Lawrence C. Parks. Boca Raton: CRC Press, 2004, p. 798.

Figure 1: MRA-1251 MSP2 Sequence

```
TGAAATTAAA ACAACAAATT TATTTATTGA AGCAATATTA CTAGAGTTAT TTAAGAGGGA TGTTCGTGCT CCACAGTTTT
CTTTGTTACC ATCGGTACAT TCTTTTTGAC TATCAGAAAGT ATTTTGTGGA TGATTATTTT TAGAACCATG CATATGTCCA
TGTTGTCCTG TACCTTTATT CTCTGGTGCA GCAGGATTTT CATTTTCTGC CGTTTGAGGT TCTTGTGGAG CTTTGGGTCC
TTCTTCAGTT GATTCATTTA ATTCATTTTG TTTTTCACCTC TCTTCTCCTT TACCGTCTGT TTTATTTGGT GCATTGCCAG
AACTTGAACT TTCTGTAGTA GTGATGGGTG GTGAAGGTGA ATTACTTTCT GTAGTAGTGA TGGGTGGTGA AGGTGAATTA
CTTTCTGTAG TAGTGATGGG TGGTGAAGGT GAATTACTTT TTGTAGCAGT AGGGGTATCA GCAGCGGTAG GAGTAGTAGT
TTGTGATTCT CCATTATTAG TAGTACTAGT ACTTGCACCTA TTTGTACTAC TTTGACTTCC ACTAGCAATA GTATCAGCTT
TTGGAGCATT TGCACCTACC CTATTAGTAT TAGAACCTTC ATTTGCCATA CTTCTCCTTA TACTCATATT ATAAGCATTG
TTTATGAATG TGTTGCTATA TTTACTTTCA TTTTAAATAT TAAAGGTAAC AAAAAATAAA
```

Figure 2: PCR Amplification of MSP2



Lane 1: Invitrogen™ TrackIt™ 100 bp DNA ladder
Lane 2: 100 ng of MRA-1251

Date: 03 DEC 2015

Signature: 

BEI Resources Authentication

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

